1700632952
[35] Delmas PD, Ensrud KE, Adachi JD, et al. For the multiple outcomes of raloxifene evaluation investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from arandomized clinical trial. J Clin Endocrinol Metab. 2002, 87
:3609-3617.
1700632953
1700632954
[36] Kelminski A. The study of tamoxifen and raloxifene（STAR trial）for the prevention of breast cancer. Hawaii Med J, 2002, 61
:209-210.
1700632955
1700632956
[37] Brown Jp, Josse RG. For the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. published corrections appear in CMAJ, 2003, 168
:400.
1700632957
1700632958
[38] Gompel A, Jacob D, de Chambine S, et al. Action of SERM and SAS（tibolone）on breast tissue. Contracept Fertil Sex. 1999, 27
:368-375.
1700632959
1700632960
[39] Beral V. Breast cancer and hormone-replacement therapy in the million women study. Lancet. 2003, 362
:419-427.
1700632961
1700632962
[40] Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study. BMJ. 1992, 305
:556-561.
1700632963
1700632964
[41] Chesnut CH III，Silverman S, Andriano K, et al. for the PROOF study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. Am J Med, 2000, 109
:267-276.
1700632965
1700632966
[42] Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Solomon Epstein Clinical Therapeutics, 2006, 28
:151-173.
1700632967
1700632968
[43] Selye H. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology, 1932, 16
:547-558.
1700632969
1700632970
[44] Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res, 1989, 4
:283-291.
1700632971
1700632972
[45] Rubin MR, Cosman F, Lindsay R, et al. The anabolic effects of parathyroid hormone. Osteoporos Int, 2002, 13
:267-277.
1700632973
1700632974
[46] Juppner H, Abou-Samra AB, Freeman M, et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science, 1991, 254
:1024-1026.
1700632975
1700632976
[47] Canalis E, Centrella M, Burch W, et al. Insulin-like growth factor Ⅰ mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest, 1989, 83
:60-65.
1700632977
1700632978
[48] Hock JM. Anabolic PTH targets proliferating cells of the primary spongiosa in young rats and increases the number differentiating into osteoblasts. J Bone Miner Res, 1994, 9
:5421.
1700632979
1700632980
[49] Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology, 1995, 136
:3632-3638.
1700632981
1700632982
[50] Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest, 1999, 104
:439-446.
1700632983
1700632984
[51] Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx 2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem, 2003, 278
:50259-50272.
1700632985
1700632986
[52] Locklin RM, Khosla S, Turner RT, et al. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem, 2003, 89
:180-190.
1700632987
1700632988
[53] Hofbauer LC, Heufelder AE. The role of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab, 2000, 85
:2355-2363.
1700632989
1700632990
[54] Ma YL, Cain RL, Halladay DL, et al. Catabolic effects of continuous human PTH [1-38] in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology, 2001, 142
:4047-4054.
1700632991
1700632992
[55] Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet, 1997, 350
:550-555.
1700632993
1700632994
[56] Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone [1-34] on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 2001, 344
:1434-1441.
1700632995
1700632996
[57] Hodsman AB, Fraher LJ, Ostbye T, et al. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest, 1993, 91
:1138-1148.
1700632997
1700632998
[58] McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med, 2005, 165
:1762-1768.
1700632999
1700633000
[59] Yonemura K, Kimura M, Miyaji T, et al. Short-term effects of vitamin K administration on prednisone-induced loss of bone mineral density in patients with chronic glomerulonephritis. Calcif Tissue Int, 2000, 66
:123-128.
1700633001
[
上一页 ]
[ :1.700632952e+09 ]
[
下一页 ]